TY - JOUR
T1 - Tenth International Conference of the Society for Integrative Oncology Translational Science in Integrative Oncology
T2 - From Bedside to Bench to Best Practices
AU - Balneaves, Lynda G.
AU - Lee, Richard T.
AU - Tomlinson Guns, Emma S.
AU - Zick, Suzanna M.
AU - Bauer-wu, Susan
AU - Greenlee, Heather
AU - Greenlee, Heather
N1 - Funding Information:
The conference received support from the National Institutes of Health’s National Cancer Institute and National Center for Complementary and Alternative Medicine (R13CA183288), the Canadian Institutes for Health Research, the Lotte and John Hecht Memorial Foundation, and the Weil Foundation.
Funding Information:
In October 2013, more than 300 researchers, clinicians, patient advocates, and patients joined together at the historic Fairmont Hotel Vancouver in Vancouver, British Columbia, Canada, for the 10th International Conference of the Society for Integrative Oncology (SIO). This conference was held to examine the growing evidence base for complementary therapies and practices currently being used in cancer care and the rapid translation of that literature into standard care and best practice guidelines. The conference theme, “Translational Science in Integrative Oncology: From Bedside to Bench to Best Practices,” encouraged conference attendees to consider how the growing evidence base on the efficacy of integrative therapies for cancer prevention and control can be effectively translated to clinical practice to improve the lives of people affected by cancer. The conference’s intensive schedule included 3 keynotes, 6 plenaries, 46 concurrent sessions, 2 interdisciplinary tumor boards, 11 workshops, and 69 posters. Another notable feature of the Conference was the hosting of 12 patient advocate scholars from the United States and Canada through an R13 grant sponsored by the National Institutes of Health’s National Cancer Institute (NCI) and National Center for Complementary and Alternative Medicine (NCCAM), bringing a wealth of knowledge and passion from their extensive experience of working with people living with cancer and their families. This funding reflects the ongoing implementation plan by SIO to create an international cohort of patient advocates who have the evidence and skills required to advocate for the uptake of evidence-based integrative therapies in cancer care. Keynote addresses were presented by medical historian Victoria Sweet, MD, PhD (University of California, San Francisco), leading physical activity researcher Kerry S. Courneya, PhD (University of Edmonton), and Frank Meyskens, MD, FACP (University of California, Irvine) who provided an overview of chemoprevention using natural health products.
PY - 2014/1
Y1 - 2014/1
N2 - The Effect of Two Types of Self-Administered Acupressure Compared to Standard of Care on Depression and Anxiety in Fatigued Breast Cancer Survivors Background: There are nearly 3 million breast cancer survivors (BCS) in the United States. Mood disorders in BCS are common, with 38% of women having moderate to high anxiety, and 22% having moderate to high depression. Depression may interfere with survivors’ quality of life, decreased adherence to adjuvant therapy and be associated with lower rates of survival. Current treatments for mood disorders can be difficult to implement and/or have unacceptable side effects; thus, there is a need for new treatments in this area. Methods: We compared the effect of 6 weeks of 2 types of self-administered acupressure (stimulating [SA] and relaxing [RA]) versus standard of care (SC) in 32 women for depression, and in 57 women with anxiety who reported ≥8 at baseline on the Hospital Anxiety Depression Scale (HADS) depression or anxiety subscales, as appropriate, and who were from an ongoing randomized clinical trial on acupressure for persistent cancer-related fatigue in BCS. Analyses of variance (ANOVA) were performed on mean differences of changes (baseline to week 6) in anxiety and depression subscales by group. Results: There was a significant decrease in depression (P =.02 vs SA; P =.06 vs SC) but not in anxiety (P =.36 vs SA; P =.46 vs SC) in the RA group compared with either SA or SC. This represents a −47% mean decrease from baseline in depression in the RA group versus −16% in the SA group and 22% in the SC group, and on average a movement from being borderline abnormal on the HADS depression subscale at baseline (9.2 ± 0.98, 0-21 point scale) to normal (4.9 ± 2.7) at 6 weeks. Conclusion: In this preliminary analysis, self-administered RA engenders a greater antidepressive response as compared with either SA or SC in fatigued BCS. These findings should be interpreted with caution given our small sample size. More rigorous studies are recommended.
AB - The Effect of Two Types of Self-Administered Acupressure Compared to Standard of Care on Depression and Anxiety in Fatigued Breast Cancer Survivors Background: There are nearly 3 million breast cancer survivors (BCS) in the United States. Mood disorders in BCS are common, with 38% of women having moderate to high anxiety, and 22% having moderate to high depression. Depression may interfere with survivors’ quality of life, decreased adherence to adjuvant therapy and be associated with lower rates of survival. Current treatments for mood disorders can be difficult to implement and/or have unacceptable side effects; thus, there is a need for new treatments in this area. Methods: We compared the effect of 6 weeks of 2 types of self-administered acupressure (stimulating [SA] and relaxing [RA]) versus standard of care (SC) in 32 women for depression, and in 57 women with anxiety who reported ≥8 at baseline on the Hospital Anxiety Depression Scale (HADS) depression or anxiety subscales, as appropriate, and who were from an ongoing randomized clinical trial on acupressure for persistent cancer-related fatigue in BCS. Analyses of variance (ANOVA) were performed on mean differences of changes (baseline to week 6) in anxiety and depression subscales by group. Results: There was a significant decrease in depression (P =.02 vs SA; P =.06 vs SC) but not in anxiety (P =.36 vs SA; P =.46 vs SC) in the RA group compared with either SA or SC. This represents a −47% mean decrease from baseline in depression in the RA group versus −16% in the SA group and 22% in the SC group, and on average a movement from being borderline abnormal on the HADS depression subscale at baseline (9.2 ± 0.98, 0-21 point scale) to normal (4.9 ± 2.7) at 6 weeks. Conclusion: In this preliminary analysis, self-administered RA engenders a greater antidepressive response as compared with either SA or SC in fatigued BCS. These findings should be interpreted with caution given our small sample size. More rigorous studies are recommended.
UR - http://www.scopus.com/inward/record.url?scp=84907424601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907424601&partnerID=8YFLogxK
U2 - 10.1177/1534735413517743
DO - 10.1177/1534735413517743
M3 - Article
C2 - 24420529
AN - SCOPUS:84907424601
SN - 1534-7354
VL - 13
SP - 5
EP - 11
JO - Integrative cancer therapies
JF - Integrative cancer therapies
IS - 1
ER -